Quantitative urinary KRAS for treatment decisions in patients with metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Melnikova, Vladislava
Vibat, Cecile Rose T.
Ning, Van
Agafitei, Raluca Dana
Hanna, Diana L.
Hancock, Saege
Erlander, Mark G.
Lenz, Heinz-Josef
Barzi, Afsaneh
机构：
[1] Trovagene Inc, San Diego, CA USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Univ Southern Calif, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15011
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Analysis of KRAS and NRAS mutations in 126 patients with KRAS exon 2 wild type for metastatic colorectal cancer (mCRC) in a single institution.
    Martin Calero, Braulio
    Llanos, Marta
    Alonso Alvarez, Beatriz
    Hernandez San Gil, Raquel
    Salido, Eduardo
    Oramas Rodriguez, Juana Maria
    Cruz, Josefina
    Rodriguez Rodriguez, Luz Milva
    Garcia Marrero, Rosa
    Ceballos Lenza, Isaac
    Lorenzo Barreto, Jose Enrique
    Rodriguez Capote, Alejandra
    Padilla Alvarez, Airam
    Gomez Camacho, Maria Nieves
    Varma, Sonal
    Norberto Batista, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
    Ricci, V.
    Vivenza, D.
    Monteverde, M.
    Strola, G.
    Granetto, C.
    Lo Nigro, C.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [33] Immune response to reovirus (REO) in phase I study with chemotherapy in patients with KRAS mutant metastatic colorectal cancer (mCRC).
    Parakrama, Ruwan
    Chaudhary, Imran
    Coffey, Matthew C.
    Goel, Sanjay
    Maitra, Radhashree
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [34] CLINICAL OUTCOMES OF BEVACIZUMAB USED IN COMMUNITY ONCOLOGY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS WITH CONFIRMED KRAS-STATUS
    Cartwright, Thomas
    Yim, Yeun Mi
    Yu, Elaine
    Rahul, Dhanda
    Tseng, Wan-Yu
    Forsyth, Michael
    Lopez, William
    ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
  • [35] Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
    Miraglio, E.
    Ricci, V.
    Vivenza, D.
    Monteverde, M.
    Strola, G.
    Granetto, C.
    Lo Nigro, C.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2015, 26 : 40 - 40
  • [36] A method to assess KRAS/BRAF genotype in patients with metastatic colorectal cancer (mCRC) elligible for anti-EGFR therapies
    Lamy, A.
    Labourier, E.
    Prigneau, O.
    Di Fiore, F.
    Sesbouea, R.
    Sabourin, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [37] COMPARISON OF KRAS TESTED AND NOT-TESTED METASTATIC COLORECTAL CANCER (MCRC) PATIENT COHORTS IN EUROPE
    Narayanan, S.
    Gallo, F.
    VALUE IN HEALTH, 2015, 18 (07) : A365 - A365
  • [38] High-resolution melting analysis (HRMA) for KRAS mutational study in patients with metastatic colorectal cancer (mCRC pts).
    De Stefano, Alfonso
    Malapelle, Umberto
    Carlomagno, Chiara
    Bianco, Roberto
    Marciano, Roberta
    Cimminiello, Carolina
    Colantuoni, Maria
    De Placido, Sabino
    Troncone, Giancarlo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [39] Direct medical cost of metastatic colorectal cancer (mCRC) treatment in Indonesia
    Kristin, Erna
    Endarti, Dwi
    Pinzon, Rizaldy Taslim
    Nugrahaningsih, Dwi ArisAgung
    Yasmina, Alfi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 303 - 303
  • [40] Latest Advance and Future Perspective for the Treatment of Metastatic Colorectal Cancer (mCRC)
    Yoshino, Takayuki
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
12345